The primary endpoint in this study is trough FEV1 response after 24 weeks. 24 weeks [clinicaltrials_resource:45332364e1fdfb991ba4a29a9bfe8f06]

The primary endpoint in this study is trough FEV1 response after 24 weeks. 24 weeks [clinicaltrials_resource:45332364e1fdfb991ba4a29a9bfe8f06]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]
Secondary outcome [clinicaltrials_vocabulary:secondary-outcome]
http://bio2rdf.org/clinicaltrials_resource:45332364e1fdfb991ba4a29a9bfe8f06
An Efficacy and Safety Study to Compare Three Doses of BEA 2180 BR to Tiotropium and Placebo in the Respimat Inhaler. [clinicaltrials:NCT00528996]
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

The primary endpoint in this study is trough FEV1 response after 24 weeks. 24 weeks [clinicaltrials_resource:45332364e1fdfb991ba4a29a9bfe8f06]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]
Secondary outcome [clinicaltrials_vocabulary:secondary-outcome]
http://bio2rdf.org/clinicaltrials_resource:45332364e1fdfb991ba4a29a9bfe8f06
Bio2RDF identifier
45332364e1fdfb991ba4a29a9bfe8f06
Bio2RDF namespace
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:45332364e1fdfb991ba4a29a9bfe8f06
measure [clinicaltrials_vocabulary:measure]
The primary endpoint in this study is trough FEV1 response after 24 weeks.
time frame [clinicaltrials_vocabulary:time-frame]
identifier
clinicaltrials_resource:45332364e1fdfb991ba4a29a9bfe8f06
title
The primary endpoint in this study is trough FEV1 response after 24 weeks. 24 weeks
@en
inDataset
type
label
The primary endpoint in this s ...... 32364e1fdfb991ba4a29a9bfe8f06]
@en